Allergy Therapeutics Cash Flow Quality Index
Allergy Therapeutics cash flow quality index. Allergy Therapeutics (AGY) has a Cash Flow Quality Index of 0.56x as of December 2021. Operating cash flow of GBX3.71 Million is below net income of GBX6.67 Million, suggesting accrual-heavy earnings not yet converted to cash. See financial flexibility index of Allergy Therapeutics to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Allergy Therapeutics (2003–2021)
Cash flow quality index of Allergy Therapeutics from 2003 to 2021. Historical Cash Flow Quality Index for Allergy Therapeutics across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore cash flow to debt ratio of Allergy Therapeutics to assess how comfortably operating cash covers total debt obligations.
Allergy Therapeutics Cash Flow Quality Index by Year (2003–2021)
Allergy Therapeutics cash flow quality index by year from 2003 to 2021. Year-by-year earnings quality comparison for Allergy Therapeutics. For the full cash flow conversion analysis, see AGY operating cash flow.
| Year | Quality Index | Operating CF (GBX) | Net Income | YoY Change |
|---|---|---|---|---|
| 2021 | 2.95x | GBX8.52 Million | GBX2.89 Million | ▲ +69.7% |
| 2020 | 1.74x | GBX12.28 Million | GBX7.06 Million | ▲ +7.7% |
| 2019 | 1.62x | GBX5.60 Million | GBX3.47 Million | ▼ -94.4% |
| 2015 | 28.92x | GBX3.12 Million | GBX108.00K | ▲ +886.1% |
| 2014 | 2.93x | GBX2.17 Million | GBX741.00K | ▼ -47.9% |
| 2013 | 5.63x | GBX2.43 Million | GBX432.00K | ▲ +25.1% |
| 2012 | 4.50x | GBX2.88 Million | GBX640.00K | ▲ +125.5% |
| 2011 | -17.63x | GBX-2.03 Million | GBX115.00K | ▼ -1607.8% |
| 2010 | 1.17x | GBX1.70 Million | GBX1.46 Million | ▼ -4.6% |
| 2004 | 1.22x | GBX1.91 Million | GBX1.56 Million | ▼ -21.7% |
| 2003 | 1.56x | GBX2.10 Million | GBX1.34 Million | — |